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Background and purpose: The inﬂuence of apolipoprotein E (ApoE) polymorphism
on clinical severity of multiple sclerosis (MS) is still controversial. Cigarette smoking
has been suggested to inﬂuence the progression of disability in these patients. In this
study, we aimed to investigate whether an interaction of smoking with the ApoE
polymorphism inﬂuences the progression of disability in MS patients.
Methods: Smoking history from 205 female patients with MS was obtained. Clinical
data collected include age at onset, disease duration, annual relapse rate, the
Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Severity Score
(MSSS). ApoE polymorphism was examined in all patients and stratiﬁed according to
smoking status and associations with the clinical data investigated.
Results: There were no signiﬁcant associations between cigarette smoking and any of
the clinical characteristics in the whole group of patients. In women carrying the ApoE
E4 isoform, smokers had a lower EDSS (P = 0.033) and MSSS (P = 0.023) in
comparison with non-smokers.
Conclusion: Our data suggest that in women with MS carrying the ApoE E4 isoform,
cigarette smoking may have a protective inﬂuence on disease progression and accu-
mulation of disability. These ﬁndings need to be conﬁrmed by future large longitudinal
studies.
Introduction
Evidence on the inﬂuence of apolipoprotein E (ApoE)
polymorphism on clinical severity of multiple sclerosis
(MS) has been controversial [1,2]. The ApoE gene exists
in three common allelic forms corresponding to the
protein isoforms E2, E3 and E4, with distinct bio-
chemical and functional properties. ApoE has been
suggested to have a role in remodelling and repairing
nervous tissue and in modifying systemic and brain
inﬂammatory responses [3,4]. Some studies have indeed
found an association between ApoE E4 allele and an
increased brain damage in these patients (for a review,
see Pinholt et al. [2]). Several confounders and
methodological issues could explain the discrepancies
between results. In particular, it is possible that
environmental and genetic factors could interact with
ApoE in modulating disease course [1]. One of these
potential confounders is exposure to tobacco smoking.
Cigarette smoking [5,6] and smoker exposure [7] have
been found to increase the risk for MS. However, an
inﬂuence of smoking on disease progression and accu-
mulation of disability [8,9] was not supported by a large
prospective study [10]. Interestingly, the risk associated
with the ApoE polymorphism has been shown to be
modulated by smoking in several situations, including
cardiovascular disease [11], age-related macular degen-
eration [12] and Alzheimers disease [13]. Based on these
data, we hypothesized that cigarette smoking could
interact with the ApoE polymorphism to modulate
disease course in MS patients.
Methods
Patients and smoking history
A total of 205 female patients with MS according to
the revised Mc Donald criteria [14] were recruited from
the MS outpatient clinic at the Neurology Service
of the Centro Hospitalar de Lisboa-Central. Our MS
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database contains laboratory and clinical data,
including information on smoking habits. The smoking
status, if not documented completely, was obtained by
telephone information with the respective patient. In
this study, we included patients aged 15–62 years and
with at least 1 year of disease duration, examined be-
tween 1995 and 2007. From this database, we collected
clinical information before the patients received
immunomodulatory or immunosuppressive treatments.
In addition, none has been treated with steroids for at
least 1 month. The clinical data collected were age at
onset of MS, disease duration, annual relapse rate, and
disease disability and severity, according to the Ex-
panded Disability Status Scale (EDSS) and the Mul-
tiple Sclerosis Severity Score (MSSS). The EDSS is the
most validated and widely accepted measure of MS
disability [15]. The MSSS is an algorithm which relates
scores on the EDSS to the distribution of disability in
patients with comparable disease durations. We
determined the Global MSSS as detailed in the article
by Roxburgh et al. [16]. The course of MS was de-
scribed as relapsing–remitting (n = 163), secondary
progressive (n = 22) and primary progressive (n =
20). Patients gave a written consent to participate in
the study, approved by the local ethics committee.
Male patients were not included in this series because
the cohort examined for the ApoE polymorphism was
not large enough for a statistical powerful analysis of
the results.
The smoking questionnaire contained questions on
current smoking status, starting and quitting dates and
number of cigarettes smoked. With one exception, all
patients who were current smokers started smoking
before the onset of MS. Ten patients stopped smoking
before the onset of the disease. Patients who never
smoked in their lives or reported to smoke fewer than
ﬁve cigarettes occasionally (not every day) were con-
sidered non-smokers. In this study, all patients labelled
smokers reported to smoke at least ﬁve cigarettes per
day. We decided not to further divide these subjects
according to the number of cigarettes smoked because
most of them reported to change their frequency of
daily consumption. There were no cigar and pipe
smokers.
ApoE typing
ApoE polymorphism was examined by using an
isoelectric focusing (IEF) method, as described
previously [17]. Brieﬂy, 15 ll of delipidated plasma
samples was run in duplicate on agarose with
sorbitol, urea, ampholine (pH 5–7) and pharmalyte
(pH 4–6.5) (Pharmacia Biotech; Amersham Pharmacia
Biotech, Little Chalfont, UK). After IEF the proteins
were electro transferred to nitrocellulose membranes
(Immobilon, pore size 0.2 lm; Millipore; Millipore
Corporate Headquarters, Billerica, MA, USA). The
membranes were sequentially incubated with poly-
clonal-goat anti-human ApoE antibody (Daichi;
Daichi Pure Chemicals, Tokyo, Japan) and IgG per-
oxidase-conjugate anti-goat antibody (Sigma; Sigma–
Aldrich Biotechnology LP, St. Louis, MO, USA). The
ApoE isoforms were visualized in a substrate solution
containing 3,3¢diaminobenzidine tetrahydrochloride
reagent (Sigma). It has been shown that for common
ApoE polymorphism, protein phenotyping is in good
agreement with DNA-based genotyping [18]. ApoE
typing was performed in blinded conditions regarding
the clinical data and smoking history of the patients.
Statistical analysis
Age, age at onset, disease duration, annual relapse rate,
EDSS and MSSS, and age at start of smoking and
number of years of smoking were compared between
E3/3 and E4/3 and between E3/3 and E2/3 patients, and
between smoker and non-smoker patients in the ApoE
phenotype subsets of subjects with analysis of variance
and Bonferroni/Dunn test. The proportions of relaps-
ing–remitting, secondary progressive and primary pro-
gressive forms were compared in the ApoE phenotype
subsets of subjects with the chi-squared test. Signiﬁ-
cance was taken to be at the two-tailed 0.05 level. All
statistical analysis was performed with the StatView 5.0
software.
Results
The demographic and clinical variables in the diﬀerent
ApoE subgroups for all women investigated are com-
pared in Table 1. The ApoE phenotypes were E3/E3
(76.6%), E4/E3 (12.7%) and E2/E3 (9.3%). Three
additional patients with the E2/E4 phenotype were ex-
cluded from the analysis. No homozygotes for the E2
and E4 alleles were detected. The observed frequencies
of ApoE alleles were comparable with the general
populations from Portugal and other countries in South
Europe [19]. No clinical diﬀerences were found to be
associated with particular ApoE alleles. Start of
smoking and years of smoking were also comparable in
the three genetic subgroups.
Patients were then stratiﬁed according to smoking
status (Table 2). No signiﬁcant clinical diﬀerences be-
tween smokers and non-smokers were observed in the
whole group of patients and in those with the E3/E3
and E2/E3 phenotypes. Ten patients who stopped
smoking before disease onset had an E3/E3 phenotype.
Excluding those subjects from the analysis did not
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change the results. In patients carrying the E4 isoform,
smokers had a lower EDSS (P = 0.033) and a lower
MSSS (P = 0.023) in comparison with non-smokers.
In these subjects, as shown in Fig. 1, half of the non-
smokers had an EDSS value and an MSSS value above
3.5 and 6, respectively, and none of the smoker
subjects was above these thresholds. Analysis of
covariance (ANCOVA) was performed in order to take
into account a possible covariation of the dependent
variable (EDSS or MSSS) with age and disease dura-
tion or with age and age at disease onset in apoE 3/4
patients. Irrespective of the combination of covari-
ables, EDSS and MSSS were signiﬁcantly lower in
smokers than in non-smokers. When the analysis was
restricted to relapsing–remitting cases these diﬀerences
became nonsigniﬁcant, possibly due to fewer numbers
of subjects included.
Discussion
Our cross-sectional study included one of the largest
cohorts of women with MS assessed for evaluating the













Age, years 38.69 ± 10.35 38.98 ± 10.26 38.42 ± 10.9 0.802 36.68 ± 10.65 0.363
Age at onset, years 31.95 ± 9.59 32.08 ± 9.41 32.12 ± 10.11 0.990 30.63 ± 9.92 0.528
Disease duration,
yearsa
5.0 (2.0–10.0) 5.0 (2.0–10.0) 5.0 (2.0–9.0) 0.927 3.0 (2.0–8.25) 0.368
Annual relapse rate 0.87 ± 0.62 0.88 ± 0.64 0.88 ± 0.59 0.980 0.79 ± 0.54 0.547
EDSS 2.57 ± 1.57 2.61 ± 1.61 2.75 ± 1.47 0.666 2.08 ± 1.35 0.164
MSSS 4.24 ± 2.49 4.24 ± 2.50 4.59 ± 2.19 0.530 3.77 ± 2.85 0.423
Disease course, n (%)
RRMS 161 (79.7) 122 (77.7) 21 (80.7) 18 (94.7)
SPMS 22 (11.1) 19 (12.1) 3 (11.5) 0.916 0 0.187
PPMS 19 (9.4) 16 (10.2) 2 (7.7) 1 (5.2)
Smokers, n (%) 72 (35.6) 51 (32.5) 11 (42.3) 10 (52.6)
Start of smoking,
years
17.29 ± 3.74 17.25 ± 3.83 16.64 ± 2.25 0.623 18.2 ± 4.71 0.471
Years of smoking 20.93 ± 8.76 21.78 ± 9.49 19.91 ± 5.84 0.521 17.7 ± 7.07 0.182
Unless otherwise indicated, data are expressed as mean ± SD. Groups compared by analysis of variance and Bonferroni/Dunn test. The
proportions of disease forms were compared by chi-squared test. EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity
Score; RRMS, relapsing–remitting MS; SPMS, secondary progressive MS; PPMS, primary progressive MS. aExpressed as median (25th–75th
percentile); P calculated as log-transformed data.







relapse rate EDSS MSSS
Total
NS (130) 38.95 ± 11.31 31.74 ± 10.08 5.0 (2.0–10.0) 0.84 ± 0.68 2.72 ± 1.60 4.38 ± 2.51
SM (72) 38.2 ± 8.5 32.35 ± 8.76 4.0 (2.0–8.5) 0.92 ± 0.50 2.31 ± 1.50 4.03 ± 2.44
P value 0.636 0.666 0.274 0.390 0.075 0.335
E3/E3
NS (106) 38.94 ± 10.93 31.47 ± 9.93 5 (2.0–10.0) 0.85 ± 0.69 2.69 ± 1.57 4.27 ± 2.49
SM (51) 39.04 ± 8.96 33.37 ± 8.29 3.0 (2.0–7.75) 0.95 ± 0.52 2.46 ± 1.67 4.23 ± 2.52
P value 0.956 0.238 0.180 0.344 0.403 0.917
E4/E3
NS (15) 39.8 ± 13 34.07 ± 11.43 5.0 (2.25–5.75) 0.87 ± 0.69 3.27 ± 1.68 5.40 ± 2.22
SM (11) 36.5 ± 7.35 29.45 ± 9.37 6.0 (2.0–11.75) 0.91 ± 0.44 2.05 ± 0.72 3.47 ± 1.66
P value 0.463 0.284 0.830 0.860 0.033 0.023
E2/E3
NS (9) 37.56 ± 13.93 31.0 ± 10.17 3.0 (1.0–10.25) 0.78 ± 0.62 2.33 ± 1.66 3.94 ± 3.05
SM (10) 35.9 ± 7.28 30.3 ± 10.22 3.5 (2.0–6.0) 0.80 ± 0.48 1.85 ± 1.03 3.61 ± 2.81
P value 0.745 0.883 0.794 0.931 0.450 0.808
Unless otherwise indicated, data are expressed as mean ± SD. NS (non-smoking) versus SM (smoking) groups compared by analysis of variance
and Bonferroni/Dunn test. EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Score. aExpressed as median (25th–75th
percentile); P calculated as log-transformed data.
834 A. Sena et al.
 2009 The Author(s)
Journal compilation  2009 EFNS European Journal of Neurology 16, 832–837
inﬂuence of ApoE polymorphism on disease severity. In
agreement with a previous study [1] our study did not
ﬁnd any clinical diﬀerences associated with ApoE al-
leles in the whole group of patients. Studies in patients
with a similar short duration of the disease (<5 years)
have shown a deleterious eﬀect of the apoE4 allele on
brain structural integrity [2]. However, the potential
pathogenic impact of this isoform suggested by this
work was not reﬂected in signiﬁcant eﬀects on clinical
disability.
Although previous studies on the inﬂuence of the
ApoE E4 allele on disability progression of MS have
been contradictory, none included information about
smoking history. Our data indicate that smoking status
may inﬂuence the impact of this allele on clinical pro-
gression in the earliest phase of the disease. It is now
well established that neuroaxonal damage begins in the
earliest stages of MS and greatly contributes to the
progression of disability late in the course of the disease
[20]. The global MSSS is considered to be the most
powerful of the current methods for measurement
severity of MS [1,16] and was suggested to correlate
with axonal damage in these patients [21]. Therefore, a
lower progression rate (MSSS) and disability (EDSS) in
smokers in comparison with non-smokers in patients
carrying the E4 isoform suggests a neuroprotective
eﬀect associated with cigarette smoking. However, it
should be noted that in agreement with another work
[10], no associations were found between smoking
status and the clinical measures in the whole study
population. This is in contrast to two other studies [8,9],
suggesting an association between ever-smoking and
progressive disease. Diﬀerences in methodology,
characteristics of patients and sample size may account
for this discrepancy. An analysis of these studies
suggests that diﬀerences in age at the start of smoking,
the daily amount of smoked cigarettes and the smoking
status before versus after the onset of MS, may con-
tribute to conﬂicting results. Moreover, as discussed in
a recent paper [7], there are individual and gender-re-
lated diﬀerences in the metabolism of smoked sub-
stances that could variably interfere with mechanisms
associated with MS. Finally, the confounding of
immunomodulatory treatments or other environmental
factors and the interaction of smoking with genetic
factors implicated in immune response, such as the
HLA-DR haplotype [7], should also be considered.
Although many tobacco smoke compounds or
smoke-related metabolites have toxic eﬀects on the
central nervous system, nicotine possibly promotes
protective mechanisms against certain inﬂammatory
and neurodegenerative processes [13,22,23]. Nicotine
has systemic immunosuppressive eﬀects [22], inhibits
microglial activation [24] and leucocyte recruitment
during inﬂammation [25] and has anti-excitotoxic [26]
and antioxidative [27] properties. These eﬀects are
mainly mediated through a7 nicotinic cholinergic
receptors. ApoE E4 isoform, in comparison with the
other isoforms, is suggested to be linked to greater
systemic and brain inﬂammatory reaction and impair-
ment of neural repair [3,4]. We could speculate that in
MS patients, smoking could counterbalance the ApoE
E4-associated promotion of brain tissue damage by


































Figure 1 Expanded Disability Status Scale (EDSS; a) and
Multiple Sclerosis Severity Score (MSSS; b) percentile values in
non-smoker (squares) and smoker (triangles) patients carrying the
APOE E4 allele.
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ment of brain cholinergic pathways has been shown to
occur in experimental allergic encephalomyelitis (EAE)
[28] and in MS patients [29,30]. Moreover, the acetyl-
cholinesterase inhibitor rivastigmine was recently ob-
served to reduce neuroinﬂammmatory and axonal
damage in EAE through a7 nicotinic receptors [31].
Taken together, our results and the reviewed data could
suggest an involvement of nicotinic receptors in the
pathogenesis of MS and that selective nicotinic phar-
macological agents should be explored as potential
useful neuroprotective strategies for these patients.
In conclusion, our results suggest that in MS patients
carrying the apoE4 isoform, cigarette smoking may
have a protective inﬂuence on disability progression.
We recognize that this study has limitations owing to
the cross-sectional design and restriction to a popula-
tion of female patients. In order to conﬁrm our data
further large longitudinal studies will be required.
Nevertheless, our ﬁndings may help explain, at least in
part, the discrepancies between individual studies
investigating separately the inﬂuence of ApoE and
smoking in disease severity of MS.
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